Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00352443 · ClinicalTrials.gov registry record · Phase 1
S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT00352443 is a Phase 1 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 66 participants.
The verdict
NCT00352443, a Phase 1 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
RATIONALE: Lapatinib and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Everolimus may also stop the growth of cancer cells by blocking blood flow to the cancer. Giving lapatinib together with everolimus may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib and everolimus in treating patients with advanced solid tumors or non-Hodgkin's lymphoma.
Interventions
- DRUG everolimus
- DRUG lapatinib ditosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2006-09 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00352443
The ClinicalTrials.gov registry entry for NCT00352443 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which everolimus is the first listed.
NCT00352443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00352443 about?
NCT00352443 is a clinical study titled "S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma". RATIONALE: Lapatinib and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Everolimus may also stop the growth of cancer cells by blocking blood flow to the cancer. Giving lapatinib together with everolimus may kill more cancer cells. PURPOSE: Th...
What is the current status of trial NCT00352443?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2006-09. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00352443?
The interventions under investigation include: everolimus (DRUG), lapatinib ditosylate (DRUG).
Who is sponsoring clinical trial NCT00352443?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.